Myriad Genetics, Inc F4Q09 (Qtr End 06/30/09) Earnings Call Transcript
SeekingAlpha.com (Free subscription) | 08/26/2009
Myriad Genetics, Inc. ( MYGN ) F4Q09 (Qtr End 06/30/09) Earnings Call August 25, 2009 4:30 am ET Complete Story »
Myriad Genetics Inc.
1Vote!
1Vote!
Market Update - MYGN - Myriad Genetics Inc. - Myriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business - Sourced WhisperFromWallStreet.com
YourFINDit.com (Free subscription) | 07/03/2009
Myriad Genetics, Inc. announced today the successful completion of the spin off of Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX - News), and that Myriad Genetics has received a Private Letter Ruling from the Internal Revenue Service that the divi ...
Videos
3Vote!
Market Update - ACOR - Acorda Therapeutics, Inc. - Drug stocks mixed; Myriad tanks on outlook - Sourced WhisperFromWallStreet.com
YourFINDit.com (Free subscription) | 07/03/2009
Drug stocks were mixed Wednesday, while shares of Myriad Genetics Inc. tanked on news that 2009 revenue would come in below its previously issued forecast.
3Vote!
Stock Alerts on Stocks in the News: ASCMA, RAVN, MYGN, ZZ, GIS, XCO
EmailWire.Com (Free subscription) | 07/02/2009
(EMAILWIRE.COM, July 02, 2009 ) DALLAS, Texas – InvestorSoup.com announces the release of Stock Alerts covering stocks in the news: Ascent Media Corp. (Nasdaq: ASCMA), Raven Industries (Nasdaq: RAVN), Myriad Genetics Inc. (Nasdaq: MYGN), Sealy Corp. (NYSE: ZZ), General Mills Inc. (NYSE: GIS) and...
4Vote!
AC Financial: AnalystChoice.com Brings You the Best Complimentary Research Report on NRGN, ORLY, MYGN and GERN
Market Wire (Free subscription) | 06/17/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Neurogen Corp. (NASDAQ: NRGN), O'Reilly Automotive Inc. (NASDAQ: ORLY), Myriad Genetics Inc. (NASDAQ: MYGN) and Geron Corporation...
3Vote!
Inverted Head and Shoulders chart pattern for 2009-06-11
DeepMarket Stock Market Blog (Free subscription) | 06/12/2009
Inverted Head and Shoulders chart found for the following stocks: Pokertek Inc. (PTEK) over a 7 day period with about a 93% match. Asiainfo Holdings Inc. (ASIA) over a 7 day period with about a 92% match. Wuhan General Group [China] In (WUHN) over a 7 day period with about a 92% match. Myriad Genetics Inc. (MYGN) over a [...]
4Vote!
WallStSense.com: WallStSense.com Free Research Report for Shareholders of ORLY, MYGN, INTU and ASML
Market Wire (Free subscription) | 05/28/2009
NEW DELHI, INDIA (MARKET WIRE) W.S.S. is an online community with a dedicated team of analysts who are providing free in-depth research on North American equities. Our analysts have issued free ratings reports on the following four companies: O'Reilly Automotive Inc. (NASDAQ: ORLY), Myriad Genetics Inc. (NASDAQ: MYGN), Intuit Inc. (NASDAQ: INTU) and ASML Holding NV (NASDAQ: ASML).
6Vote!
Gene patents
Later On (Free subscription) | 05/16/2009
I believe that patenting genes is a wrong-headed idea, so I thought this post by Rebecca Skloot was excellent. It begins: Earlier this week, the American Civil Liberties Union and several other groups filed suit against Myriad Genetics — the company that holds the patent on the breast cancer gene. They’re hoping to get the breast [...]
3Vote!
Myriad Genetics Lawsuit Will Become Landmark Case: ACLU
Medical News Today (Free subscription) | 05/16/2009
The American Civil Liberties Union action in filing a lawsuit against Myriad Genetics is going to lead to one of the most important legal battles in the history of biotechnology, asserts Genetic Engineering & Biotechnology News (GEN). The ACLU charged that the patenting of two human genes linked to breast and ovarian cancer will inhibit medical research. The organization also claims that the patents...
Explore : Genetics
1Vote!
Patenting the "Breast Cancer gene"
Gene Expression (Free subscription) | 05/16/2009
Rebecca Skloot has a piece up in Double X , Slate's new webzine, on the controversy around Myriad Genetics . Read the comments on this post...
1Vote!
Myriad Genetics Lawsuit Will Become Landmark Case
Red Orbit (Free subscription) | 05/15/2009
The American Civil Liberties Union action in filing a lawsuit yesterday against Myriad Genetics is going to lead to one of the most important legal battles in the history of biotechnology, asserts Genetic Engineering & Biotechnology News (GEN).
3Vote!
Lawsuit Filed Over Gene Patent
Medical News Today (Free subscription) | 05/15/2009
A group of cancer patients, genetic researchers and professional pathologist organizations has filed a lawsuit against Myriad Genetics and the U.S. Patent Office over the patent of two genes associated with an increased risk of breast and ovarian cancers, the New York Times reports.
4Vote!
Indiana University Law Professor Available to Discuss ACLU Gene Patent Lawsuit
Newswise (Free subscription) | 05/14/2009
The American Civil Liberties Union filed a lawsuit (May 11) against the Patent and Trademark Office, Myriad Genetics, and the University of Utah Research Foundation for patenting two genes associated with hereditary breast and ovarian cancers. Yvonne Cripps, the Harry T. Ice Professor of Law at Indiana University Maurer School of Law, says this is likely to be a landmark case.
5Vote!
Lawsuit Filed on Patents of Genes Associated with Breast Cancer
Feminist Daily News (Free subscription) | 05/14/2009
A lawsuit filed this week in a US District Court by the ACLU charges that patents of two genes associated with breast and cervical cancer violate the first amendment and are invalid because genes are a "product of nature." Myriad Genetics and the University of Utah Research Foundation currently hold...
4Vote!
ACLU wants patents on gene tests declared unconstitutional
bioethics.com (Free subscription) | 05/14/2009
The ACLU has organized a collection of patients, clinicians, and medical organizations and filed a suit that seeks to overturn patents awarded to Myriad Genetics, which uses them to enforce its monopoly on testing for genetic changes associated with breast cancer. (Ars Technica)